TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03440216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: * temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: * temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue sampling (lung)
Description: Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue sampling (lung)
Description: Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collection of fluid samples
Description: Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collection of fluid samples
Description: Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
Study: NCT04095286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
Study: NCT04266652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth block
Description: tooth root blocks were used to increase the bone width

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous bone block
Description: autogenous bone block were used to increase the bone width
Study: NCT03633552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
Study: NCT00063882

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy (100/110)
Description: 100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy (125/145)
Description: 125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
Study: NCT03756883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate and Salmeterol Inhalation Powder
Description: 100/50 mcg per actuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate and Salmeterol Inhalation Powder
Description: 100/50 mcg per actuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Powder
Description: No active content
Study: NCT00707421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorometholone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artificial lacrimal tears
Study: NCT00328484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Activity Program
Description: The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
Study: NCT01392326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab (75 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab (150 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study: NCT03527004

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in IQOS users residing in Italy.
Study: NCT03920306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-acid treatment
Description: This study investigates a bundle of three commonly used treatments
Study: NCT03201978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% CREAM
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2894512 MATCHING VEHICLE CREAM
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
Study: NCT03992547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted Gait Training
Description: SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
Study: NCT03388502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (SMS) Bot (intervention group)
Description: Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine perioperative education & teaching (control group)
Description: Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
Study: NCT04237584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lead-in Enzalutamide followed by Radium-223/Enzalutamide
Description: After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
Study: NCT03126084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
Study: NCT04237584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lead-in Enzalutamide followed by Placebo/Enzalutamide
Description: After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.

Intervention type: DRUG
Group type: OTHER
Intervention: Darolutamide during Lead-in Period
Description: Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
Study: NCT04095286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
Study: NCT04237584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lead-in Darolutamide followed by Radium-223/Darolutamide
Description: After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
Study: NCT03583021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Sugammadex of 3 mg/kg is injected.
Study: NCT04237584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lead-in Darolutamide followed by Placebo/Darolutamide
Description: After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
Study: NCT03864848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Touch Implant
Description: The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
Study: NCT03583021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine Injectable Product
Description: Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
Study: NCT03303729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Hydrolysate
Description: 25 grams of meat hydrolysate to maximally stimulate protein synthesis.
Study: NCT04565522

Intervention type: OTHER
Intervention: Prospective observation
Description: Prospective observation until one year follow-up

Intervention type: OTHER
Intervention: Prospective observation
Description: Prospective observation until one year follow-up
Study: NCT03303729

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat Hydrolysate
Description: 25 grams of meat hydrolysate to maximally stimulate protein synthesis.
Study: NCT02242929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream with prior curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical excision
Study: NCT00695006

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Traction
Description: Traction \<5lbs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction
Description: Standard supine intermittent traction
Study: NCT00739102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.M.A.R.T. ® Stent
Description: The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
Study: NCT02457702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orally administered labeled glycerol
Description: Oral administration of labeled glycerol
Study: NCT00868595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-101
Description: Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: Activating agent, infusion
Study: NCT04095286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
Study: NCT05234814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
Description: Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy
Description: Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006).
Study: NCT04095286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
Study: NCT03535701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo ketogenic diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given standard of care therapy with paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given standard of care therapy with paclitaxel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04498533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: forearm strap (counterforce brace)
Study: NCT03303729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cluster Dextrin
Description: 75 grams of Cluster Dextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 75 grams of Glucose
Study: NCT00810602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduced intensity, related donor stem cell transplant
Description: Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (standard GVHD prophylaxis)
Description: Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate (standard GVHD prophylaxis)
Description: Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study.
Study: NCT01396421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712 [Brexpiprazole] High Dose
Description: Higher dose, tablet, once daily, for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
Description: Middle dose, tablet, once daily, for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: OPC-34712 [Brexpiprazole] Low Dose
Description: Lower dose, tablet, once daily, for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for six weeks
Study: NCT00392782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.